Tokai Pharmaceuticals (NASDAQ: NVUS) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Tokai Pharmaceuticals to similar companies based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, risk, dividends and profitability.

Valuation and Earnings

This table compares Tokai Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Tokai Pharmaceuticals N/A -$37.95 million -1.03
Tokai Pharmaceuticals Competitors $564.12 million $96.15 million 56.53

Tokai Pharmaceuticals’ competitors have higher revenue and earnings than Tokai Pharmaceuticals. Tokai Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Tokai Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tokai Pharmaceuticals N/A -156.99% -140.33%
Tokai Pharmaceuticals Competitors -13,605.34% -145.85% -26.11%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Tokai Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tokai Pharmaceuticals 0 0 0 0 N/A
Tokai Pharmaceuticals Competitors 131 798 1740 59 2.63

As a group, “Biopharmaceuticals” companies have a potential upside of 13.54%. Given Tokai Pharmaceuticals’ competitors higher probable upside, analysts plainly believe Tokai Pharmaceuticals has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

38.9% of Tokai Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 5.2% of Tokai Pharmaceuticals shares are owned by insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Tokai Pharmaceuticals has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Tokai Pharmaceuticals’ competitors have a beta of 1.25, suggesting that their average stock price is 25% more volatile than the S&P 500.

Summary

Tokai Pharmaceuticals competitors beat Tokai Pharmaceuticals on 8 of the 9 factors compared.

Tokai Pharmaceuticals Company Profile

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.